SavedAdd your journal

Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2013 / Cilt: 21 - Sayı: 3

Chemotherapy-induced venous thromboembolism in patients with breast cancer

Meme kanserli hastalarda kemoterapiye bağlı venöz tromboemboli

Mustafa Kemal DEMİRAĞ
Yasemin TÜRKMEN
Pages
654–658
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median age was higher in patients with thromboembolism (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: This study aims to investigate the clinical presentation of venous thromboembolism (VTE) in patients with breast cancer undergoing chemotherapy.
📊
Key Findings & Data:Methods: Between January 2008 and December 2012, 500 women who were diagnosed with grade 1, 2 or 3 breast cancer and underwent postoperative chemotherapy to prevent recurrences at Ondokuz Mayıs University, Faculty of Medicine, Department of Oncology were included.
💡
Conclusion & Impact:The median age was higher in patients with thromboembolism (p
🔬Design:Review & Systematic Survey
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: This study aims to investigate the clinical presentation of venous thromboembolism (VTE) in patients with breast cancer undergoing chemotherapy. Methods: Between January 2008 and December 2012, 500 women who were diagnosed with grade 1, 2 or 3 breast cancer and underwent postoperative chemotherapy to prevent recurrences at Ondokuz Mayıs University, Faculty of Medicine, Department of Oncology were included. All data were reviewed by the experts at Ondokuz Mayıs University, Faculty of Medicine, Department of Cardiovascular Surgery. Results: The median age was 70 years (range, 32 to 76 years) in patients with VTE and 48 years (range, 23 to 76 years) in patients without VTE. Eleven patients (2.2%) had VTE. The median age was higher in patients with thromboembolism (p

Özet

Amaç: Bu çalışmada venöz tromboembolinin (VTE) kemoterapi uygulanan meme kanserli hastalardaki klinik özellikleri incelendi. Ça­lış­ma pla­nı: Ocak 2008 - Aralık 2012 tarihleri arasında Ondokuz Mayıs Üniversitesi Tıp Fakültesi Onkoloji Kliniğinde evre 1, 2 veya 3 meme kanseri tanısı konulan ve ameliyat sonrası nüksü önleme amaçlı kemoterapi uygulanan 500 kadın hasta çalışmaya alındı. Elde edilen tüm veriler, Ondokuz Mayıs Üniversitesi Tıp Fakültesi Kalp ve Damar Cerrahisi Kliniği uzmanları tarafından değerlendirildi. Bul­gu­lar: Medyan yaşı VTE geçiren hastalarda 70 yıl (dağılım, 32-76 yıl) iken, VTE geçirmeyen hastalarda 48 yıl (dağılım, 23-76 yıl) idi. On bir hastada (%2.2) VTE saptandı. Tromboemboli geçiren hastalarda medyan yaş daha yüksek idi (p

🔖

Cite This Article

DEMİRAĞ, M. K., TÜRKMEN, Y. (2022). Chemotherapy-induced venous thromboembolism in patients with breast cancer. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 21 - Sayı: 3, 654–658. https://ajindex.com/articles/624604

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Özyılkan Ö, Yıldırım Y. Kanserin tromboembolik komplikasyonları ve tedaviye yönelik yaklaşımlar. Acta Oncologica Turcica 2009;42:86-91
  2. Chavez-MacGregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, et al. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol 2011;22:2394-402. doi: 10.1093/ annonc/mdq777
  3. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I17-21
  4. American Cancer Society. Breast cancer facts and figures 2007-2008. Atlanta, GA: American Cancer Society; 2009
  5. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-6
  6. Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994;12:1266-71
  7. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9
  8. Sarıgül A, Tanyeli Ö. Derin ven trombozunda güncel tedavi yaklaşımları. Turk Gogus Kalp Dama 2007;15:316-21
  9. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001;106:6-12
  10. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-7
  11. Mandala M, Falanga A, Labianca R. Video meliora proboque sed deteriora sequor: the case of thromboprophylaxis in hospitalized cancer patients. Ann Oncol 2010;21:911-3. doi: 10.1093/annonc/mdp500
  12. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94
  13. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984;54:1264-8
  14. Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer 2008;99:1000-6. doi: 10.1038/sj.bjc.6604620
  15. Canobbio L, Fassio T, Ardizzoni A, Bruzzi